StockNews.com Downgrades IQVIA (NYSE:IQV) to Hold

IQVIA (NYSE:IQVGet Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Other analysts also recently issued reports about the stock. Mizuho lowered their price target on shares of IQVIA from $300.00 to $270.00 and set a “buy” rating on the stock in a report on Monday, March 7th. Guggenheim initiated coverage on shares of IQVIA in a report on Monday, May 23rd. They set a “buy” rating and a $244.00 price target on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of IQVIA from $250.00 to $290.00 and gave the stock a “buy” rating in a research report on Tuesday, April 12th. Piper Sandler upgraded shares of IQVIA from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $231.00 to $255.00 in a research report on Thursday, April 28th. Finally, Barclays reduced their price objective on shares of IQVIA from $275.00 to $240.00 in a research report on Thursday, April 28th. Two equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $277.80.

IQV stock opened at $211.54 on Wednesday. The firm’s fifty day simple moving average is $212.57 and its 200-day simple moving average is $233.50. The company has a market capitalization of $40.04 billion, a P/E ratio of 38.12, a price-to-earnings-growth ratio of 1.42 and a beta of 1.41. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.93 and a quick ratio of 0.93. IQVIA has a 12 month low of $194.67 and a 12 month high of $285.61.

IQVIA (NYSE:IQVGet Rating) last released its quarterly earnings data on Wednesday, April 27th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.27 by $0.07. IQVIA had a net margin of 7.69% and a return on equity of 28.80%. The business had revenue of $3.57 billion for the quarter, compared to the consensus estimate of $3.54 billion. During the same period in the prior year, the firm earned $2.05 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. As a group, sell-side analysts forecast that IQVIA will post 9.48 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in IQV. Riverview Trust Co purchased a new position in IQVIA during the first quarter worth about $25,000. UMB Bank N A MO purchased a new position in IQVIA during the fourth quarter worth about $26,000. Dividend Assets Capital LLC purchased a new position in IQVIA during the first quarter worth about $27,000. Johnson Financial Group Inc. purchased a new position in IQVIA during the fourth quarter worth about $34,000. Finally, Quent Capital LLC boosted its stake in IQVIA by 271.8% during the first quarter. Quent Capital LLC now owns 145 shares of the medical research company’s stock worth $34,000 after buying an additional 106 shares during the period. 87.12% of the stock is owned by institutional investors.

IQVIA Company Profile (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.